Thick smog enveloped New Delhi as the Indian capital’s air quality was classified as 'very poor.' Authorities stepped up anti-pollution measures, including restricting the entry of older, high-emission vehicles

⚡Funding Brief⚡ Enveda is a clinical-stage biotech based in Boulder, Colorado. It uses its AI platform, PRISM, to identify drug candidates in natural chemistry from plants and microbes, then develops them into oral medicines. The company says it has produced about 17 development candidates since its 2019 founding, three of which are now in human trials. None has been approved by any regulator. Per the company's press release and TechCrunch on 23 Sep 2026, Enveda raised $311 million in a Series E at a valuation of about $2 billion, according to TechCrunch, roughly double its valuation a year earlier. Catalio Capital Management led the round, with new investors including Durable Capital, ICONIQ, Lightspeed and Surveyor Capital (a Citadel company), and existing backers such as Baillie Gifford, True Ventures and Lux Capital also participating. Total capital raised now exceeds $845 million. The round follows positive early clinical results this year for ENV-294 (atopic dermatitis) and ENV-308 (metabolic health after stopping GLP-1 drugs). Proceeds will move both into later-stage trials, advance ENV-6946 (inflammatory bowel disease) through mid-stage trials, and scale the PRISM platform. Source: Enveda / BioSpace press release, TechCrunch, 2026-09-23

AI BIOTECH ENVEDA DOUBLES VALUATION TO $2B Enveda has raised new funding led by Catalio Capital alongside Iconiq, doubling its valuation to $2 Billion. The company uses AI to discover drugs from plants and microbes and has produced 17 candidates since 2019, including pills targeting post-GLP-1 weight maintenance, atopic dermatitis and inflammatory bowel disease.

Big news today: @Envestnet_ entered a definitive agreement to acquire @Vestmark! I’ve been involved in dozens of exits, but this one is very close to my heart. I started Vestmark with my fraternity brothers (and my actual brother), writing the first few lines of code myself by hand, all the way through today where the company supports 2T+ in assets, 5+ million accounts, and is leading the way with cutting edge AI solutions in a heavily regulated space. I’m so proud of the 100s of incredible individuals who made it their life mission to build Vestmark, working alongside me, and then carrying the torch beyond my time as a 9-9-6 founder. We only got here because of you! I’m also grateful for all of those who worked so diligently to unite these two great companies: the employees, the leadership teams, the respective boards, and an extra shoutout to Karl Roessner and Colin Motley. Looking ahead, I’m comforted knowing Vestmark will be in the extremely capable hands of Chris Todd, a trusted, seasoned operator in the space. This is just the team to maintain Vestmark’s trajectory! As this chapter comes to a close, I’ve got a lot to look forward to. I’m back to working deep in the code, building something new and close to my MIT roots. Stay tuned for the launch! -Dave Blundin The deal is expected to close in the fourth quarter, subject to customary closing conditions. Press Release here:

“Pushing the envelope in virtually every aspect possible.” @ServeTheHome takes a deep dive into AMD Instinct MI455X and CDNA 5, exploring the memory, bandwidth, packaging and rack-scale advances behind the next era of Instinct accelerators. 🚀